Fulgent Genetics Raises FY24 Adj EPS Guidance From $(0.30) to $0.33 Vs $(0.39) Est; Affirms Sales Guidance Of $280.00M Vs $282.16M Est
Fulgent Genetics Raises FY24 Adj EPS Guidance From $(0.30) to $0.33 Vs $(0.39) Est; Affirms Sales Guidance Of $280.00M Vs $282.16M Est
fulgent genetics将FY24调整后的每股收益指引从$(0.30)调整至$0.33，预期为$(0.39);确认销售指引为$28000万，预期为$28216万
Outlook:
展望：
For the full year 2024, Fulgent expects:
核心收入约为28000万美元
- Core Revenue of approximately $280 million
- GAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per share
- Non-GAAP loss improvement from approximately ($0.30) loss per share to approximately $0.33 income per share
- Cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024*
- GAAP亏损从每股约($2.25)降至每股约($1.95)
- 按照通用会计准则（GAAP），每股亏损从约（$1.95）改善为约（$1.70）
- 非通用会计准则（Non-GAAP）每股亏损从约（$0.30）改善为约$0.33每股收入
- 截至2024年12月31日，现金、现金等价物和可交易证券的投资约为8000万美元*
*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company's ongoing stock repurchase program or other expenditures outside the ordinary course of business.
由于公司正在进行股票回购计划或其他业务常规范围之外的支出等各种因素和情况的影响，现金支出可能高于或低于当前估算值。
资讯热榜
更新时间